DE60133385D1 - (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen - Google Patents

(+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen

Info

Publication number
DE60133385D1
DE60133385D1 DE60133385T DE60133385T DE60133385D1 DE 60133385 D1 DE60133385 D1 DE 60133385D1 DE 60133385 T DE60133385 T DE 60133385T DE 60133385 T DE60133385 T DE 60133385T DE 60133385 D1 DE60133385 D1 DE 60133385D1
Authority
DE
Germany
Prior art keywords
piperidinethanol
dimethoxyphenyl
prodrug
fluoro
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60133385T
Other languages
English (en)
Other versions
DE60133385T2 (de
Inventor
Richard Scheyer
Stephen Sorensen
Janice Hitchcock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of DE60133385D1 publication Critical patent/DE60133385D1/de
Application granted granted Critical
Publication of DE60133385T2 publication Critical patent/DE60133385T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
DE60133385T 2000-05-25 2001-05-23 (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen Expired - Fee Related DE60133385T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20694300P 2000-05-25 2000-05-25
US206943P 2000-05-25
PCT/US2001/016653 WO2001089498A2 (en) 2000-05-25 2001-05-23 USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS

Publications (2)

Publication Number Publication Date
DE60133385D1 true DE60133385D1 (de) 2008-05-08
DE60133385T2 DE60133385T2 (de) 2009-04-23

Family

ID=22768607

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60133385T Expired - Fee Related DE60133385T2 (de) 2000-05-25 2001-05-23 (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen

Country Status (20)

Country Link
US (3) US20020099076A1 (de)
EP (1) EP1289527B1 (de)
JP (1) JP2003535058A (de)
KR (1) KR100784655B1 (de)
CN (1) CN1436078A (de)
AR (1) AR029666A1 (de)
AT (1) ATE390134T1 (de)
AU (2) AU6484201A (de)
BR (1) BR0111102A (de)
CA (1) CA2410554C (de)
DE (1) DE60133385T2 (de)
DK (1) DK1289527T3 (de)
ES (1) ES2300333T3 (de)
IL (1) IL152908A0 (de)
MX (1) MXPA02011511A (de)
NO (1) NO20025630L (de)
NZ (1) NZ522659A (de)
PT (1) PT1289527E (de)
TW (1) TWI299001B (de)
WO (1) WO2001089498A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050025628A (ko) 2002-07-19 2005-03-14 바이오비트럼 에이비 5-ｈｔ2ａ 수용체 관련 장애의 치료를 위한 신규피페라지닐-피라지논 유도체
ES2359725T3 (es) * 2004-09-30 2011-05-26 F. Hoffmann-La Roche Ag Composiciones y métodos para el tratamiento de trastornos cognitivos.
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
DE102006040278A1 (de) * 2006-08-21 2008-03-20 Technische Universität Dresden Arzneimittel zur Behandlung des Charles-Bonnet-Syndroms
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017172757A1 (en) * 2016-03-29 2017-10-05 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (de) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulierungen von pimavanserin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021428A (en) 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US4783471A (en) 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
US4912117A (en) 1985-07-02 1990-03-27 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4877798A (en) 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
ATE102482T1 (de) 1988-01-21 1994-03-15 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
US5106855A (en) 1989-12-20 1992-04-21 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
JP2869512B2 (ja) * 1990-06-01 1999-03-10 メレルダウファーマスーティカルズ インコーポレイテッド （＋）―α―（２，３―ジメトキシフェニル）―１―［２―（４―フルオロフェニル）エチル］―４―ピペリジンメタノール
US6004980A (en) 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
EP0796619A1 (de) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
WO1999020315A1 (en) * 1997-10-23 1999-04-29 The Research Foundation Of State University Of New York Methods of screening potential atypical antipsychotic drugs
KR100764532B1 (ko) * 1998-08-28 2007-10-09 아벤티스 파마슈티칼스 인크. Ｒ(+)-α-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올의 수면 장애 치료용 약제학적 조성물
CA2347469C (en) * 1998-10-14 2006-02-28 Aventis Pharmaceuticals Inc. Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 100,907
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same

Also Published As

Publication number Publication date
IL152908A0 (en) 2003-06-24
ES2300333T3 (es) 2008-06-16
MXPA02011511A (es) 2003-04-25
AR029666A1 (es) 2003-07-10
WO2001089498A3 (en) 2002-05-10
EP1289527A2 (de) 2003-03-12
US20020099076A1 (en) 2002-07-25
EP1289527B1 (de) 2008-03-26
AU6484201A (en) 2001-12-03
NO20025630L (no) 2003-01-24
NZ522659A (en) 2004-06-25
NO20025630D0 (no) 2002-11-22
DE60133385T2 (de) 2009-04-23
BR0111102A (pt) 2003-03-11
KR20030034078A (ko) 2003-05-01
AU2001264842B2 (en) 2005-01-27
CN1436078A (zh) 2003-08-13
PT1289527E (pt) 2008-05-13
PL359176A1 (en) 2004-08-23
KR100784655B1 (ko) 2007-12-12
TWI299001B (en) 2008-07-21
US20040204457A1 (en) 2004-10-14
CA2410554C (en) 2009-02-03
ATE390134T1 (de) 2008-04-15
CA2410554A1 (en) 2001-11-29
DK1289527T3 (da) 2008-07-14
US20030036553A1 (en) 2003-02-20
JP2003535058A (ja) 2003-11-25
US7132433B2 (en) 2006-11-07
WO2001089498A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019195D1 (de) Behandlung durch Ablation von Knochenmetastasen
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
NO20040936L (no) Plaster for behandling av dysfunksjoner og forstyrrelser ved neglevekst.
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE250605T1 (de) Piperidin verbindung zur behandlung von psoriasis
NO20014047D0 (no) Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE297917T1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60133385D1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
IS5951A (is) 5HT1 mótlyf fyrir meðferð gegn þunglyndi
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60130365D1 (de) Die Verwendung von Rosiglitazon zur Behandlung von psychiatrischen Erkrankungen.
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE253578T1 (de) Oxazinochinolone zur behandlung von viralen infektionen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS HOLDINGS INC., GREENVILLE, DEL., US

8339 Ceased/non-payment of the annual fee